Evotec Stock: Confidence Wanes
Evotec’s share price has fallen sharply over the past year, dropping by roughly 37%. The biotech firm now trades near its 52-week low, with recent financial results adding to investor concerns. A key shareholder has also cut its stake, deepening the slump.
In December 2025, Novo Nordisk, Evotec’s second-largest shareholder, sold 9.4 million shares—around 5% of the company’s capital. The Danish pharmaceutical giant had first invested in Evotec through a capital increase in 2017. This move follows a broader reduction in holdings by Novo Holdings, a long-term major investor.
Evotec’s financial struggles became clearer in its third-quarter 2025 report. The company posted a loss per share of €0.24, worse than the same period a year earlier. Revenue also declined, pointing to weaker day-to-day business performance. The stock currently sits at about €5.24, just above its 52-week low of €5.12. Analysts warn that a drop below the €5.00 mark—a key psychological and structural support level—could spark further selling. If breached, this threshold may accelerate the stock’s decline.
Evotec’s share price remains under pressure, trading near its lowest point in a year. With revenue and earnings both falling, and a major shareholder reducing its position, the company faces a challenging outlook. The €5.00 level will be critical in determining whether the stock stabilises or falls further.
